<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067389</url>
  </required_header>
  <id_info>
    <org_study_id>HCP-018</org_study_id>
    <nct_id>NCT03067389</nct_id>
  </id_info>
  <brief_title>Combined Breast Cancer Risk Study</brief_title>
  <official_title>Evaluation of a Combined Breast Cancer Risk Derived From a Polygenic Risk Score and the Tyrer-Cuzick Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Myriad Genetic Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Myriad Genetic Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, non-interventional study in women 18 to 84 years of age. Subjects will provide
      a sample for genetic testing and information about their medical and family history. The
      results of the genetic test will be combined with clinical data to validate a method of
      predicting breast cancer risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, non- interventional study. Women presenting at imaging centers for
      routine breast cancer screening or breast cancer diagnostic assessment and who provide
      written informed consent will undergo genetic testing. Subjects will also provide information
      about their personal medical and cancer history and family cancer history. The results of the
      genetic test will be combined with the subject's clinical information, family history, and a
      risk assessment model to validate a new method of predicting breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate that a combined breast cancer risk derived from a polygenic risk score and a breast cancer risk assessment model is a better predictor of breast cancer than the risk assessment model alone</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To derive a distribution of polygenic risk scores in an unselected patient population</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hereditary Cancer</condition>
  <arm_group>
    <arm_group_label>History of invasive breast cancer</arm_group_label>
    <description>Subjects with a diagnosis of invasive breast cancer within the past 12 months will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No history of invasive breast cancer</arm_group_label>
    <description>Subjects with no history of breast cancer will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnostic test</intervention_name>
    <description>Genetic diagnostic test</description>
    <arm_group_label>History of invasive breast cancer</arm_group_label>
    <arm_group_label>No history of invasive breast cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood and saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women presenting at imaging centers for a breast cancer diagnostic assessment visit or
        preventative screening visit.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Women without breast cancer:

          -  18 to 84 years of age

          -  Western/Northern European, Central/Eastern European, or Ashkenazi ancestry

          -  No history of invasive breast cancer

        Women with a history of breast cancer:

          -  18 to 84 years of age

          -  Western/Northern European, Central/Eastern European, or Ashkenazi ancestry

          -  Pathologically confirmed invasive breast cancer diagnosed within the past 12 months

        Exclusion Criteria:

          -  Unwilling to provide written informed consent

          -  Women with history of ductal carcinoma in situ (DCIS).

          -  Patient has had a prior breast biopsy, exclusive of a breast biopsy diagnostic of
             breast cancer, that showed either hyperplasia, atypical hyperplasia, lobular carcinoma
             in situ (LCIS), or the specific histologic result is unknown to the patient
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Holmsn, MD</last_name>
    <role>Study Director</role>
    <affiliation>Myriad Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Holman, MD</last_name>
    <phone>801-584-3090</phone>
    <email>jholman@myriad.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Breast Center of Northwest Arkansas</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audra Flammang</last_name>
      <phone>479-601-3789</phone>
      <email>AudraFlammang@me.com</email>
    </contact>
    <contact_backup>
      <last_name>Danna Grear, MD</last_name>
      <email>Danna.Grear@mana.md</email>
    </contact_backup>
    <investigator>
      <last_name>Danna Grear, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bethesda Health</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica McAfee, MSN, ARPN</last_name>
      <phone>561-374-5353</phone>
      <email>JMcAfee@Bhinc.org</email>
    </contact>
    <contact_backup>
      <last_name>Rosa Yunes</last_name>
      <email>ryunes@rpna.net</email>
    </contact_backup>
    <investigator>
      <last_name>Carol Adami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cuda Women's Health Center</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Conroy</last_name>
      <phone>508-957-1623</phone>
      <email>lconroy@capecodhealth.org</email>
    </contact>
    <investigator>
      <last_name>Kathryn Dalton, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elizabeth Wende Breast Care</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Salamone, CGC</last_name>
      <phone>575-758-7057</phone>
      <email>jsalamone@ewbc.com</email>
    </contact>
    <investigator>
      <last_name>Wade Hedegard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

